EXBIO has recently developed two new products for multicolor flow-cytometric immunophenotyping of cells of the human immune system from peripheral blood to follow up kinetics of immune responses in relation to clinical and virological features of a COVID-19 patients. Design of these new products reflects the recently published reports (1,2,3).
Now, we bring you a presentation of patient’s data – comparision with percentage range acquired from normal healthy donors and time-course changes in subpopulations of B and T cells of hospitalized patients diagnosed with COVID-19 – day 1, day 4 and day 11 from hospitalization.
Our products DryFlowEx ASC Screening Kit and DryFlowEx ACT T Screening Kit are designed for very simple use - in order to minimize hands-on-time and contacts with the infectious blood specimen, the reagents are provided in a ready-to-use single-test tube format. Each tube (standard 12 x 75 mm flow cytometry tube) contains a layer with the dried pre-formulated mixture of antibody conjugates for direct labeling of target cells.
Simple laboratory workflow enables operator to follow just three easy steps:
Fig. 1 Target population(s) percentage change in time acquired from whole blood specimens of hospitalized patients diagnosed with COVID-19
Technical and application support: firstname.lastname@example.org
Availability of products, price quotations: email@example.com
(1) Thevarajan, I., Nguyen, T.H.O., Koutsakos, M. et al. Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19. Nat Med (2020).
(2) Xu Z., Shi L., Wang Y. et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med (2020).
(3) Guang Chen G., Zhao J., Ning Q. et al. Clinical and immunologic features in severe and moderate Coronavirus Disease 2019. J Clin Invest. (2020).
European Commission extended deadlines for the implementation of the new IVDR (Regulation No. 2017/746) in order to avoid disruption of the supply of in vitro medical devices.
Accordingly to most recent studies, SCIMP appears to be a key, well defined component in initiation TLR-mediated pro-inflammatory responses in macrophages.
Today we introduce four mouse monoclonal antibody clones, that have been added to our portfolio: Anti-human TROP2 (clone TrMab-6), anti-human TCR gamma/delta (clone 11F2), anti-human CD272 (MIH26), anti-human granzyme A (CB9).